These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29335263)

  • 1. Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.
    Udow SJ; Freitas ME; Fox SH; Lang AE
    CMAJ; 2018 Jan; 190(2):E50-E52. PubMed ID: 29335263
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments.
    Chou KL; Messing S; Oakes D; Feldman PD; Breier A; Friedman JH
    Clin Neuropharmacol; 2005; 28(5):215-9. PubMed ID: 16239760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.
    Morgan CJ; Curran HV
    Br J Psychiatry; 2008 Apr; 192(4):306-7. PubMed ID: 18378995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosis associated with synthetic cannabinoid agonists: a case series.
    Hurst D; Loeffler G; McLay R
    Am J Psychiatry; 2011 Oct; 168(10):1119. PubMed ID: 21969050
    [No Abstract]   [Full Text] [Related]  

  • 5. Cannabis and cannabinoids.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):97-8. PubMed ID: 27466748
    [No Abstract]   [Full Text] [Related]  

  • 6. Products containing synthetic cannabinoids and psychosis.
    Brakoulias V
    Aust N Z J Psychiatry; 2012 Mar; 46(3):281-2. PubMed ID: 22391292
    [No Abstract]   [Full Text] [Related]  

  • 7. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical marijuana and the mind. More is known about the psychiatric risks than the benefits.
    Harv Ment Health Lett; 2010 Apr; 26(10):1-3. PubMed ID: 20499454
    [No Abstract]   [Full Text] [Related]  

  • 9. Synthetic cannabinoid overdose in a 20-year-old male US soldier.
    Berry-Cabán CS; Ee J; Ingram V; Berry CE; Kim EH
    Subst Abus; 2013; 34(1):70-2. PubMed ID: 23327506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic cannabinoid-induced psychosis: two adolescent cases.
    Oluwabusi OO; Lobach L; Akhtar U; Youngman B; Ambrosini PJ
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):393-5. PubMed ID: 23083027
    [No Abstract]   [Full Text] [Related]  

  • 11. [Differential approaches to the treatment of acute psychosis due to the use of synthetic cannabinoids].
    Kekelidze ZI; Klimenko TV; Kozlov AA; Shakhova SM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(12):21-26. PubMed ID: 29376979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Cannabinoids.
    Mills B; Yepes A; Nugent K
    Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug induced psychosis.
    Allebeck P; Andréasson S
    Br J Psychiatry; 1996 Jul; 169(1):114-5. PubMed ID: 8818382
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cannabis and cannabinoids as drugs].
    Khiabani HZ; Mørland J
    Tidsskr Nor Laegeforen; 2007 Mar; 127(5):579-82. PubMed ID: 17332810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient.
    Peglow S; Buchner J; Briscoe G
    Am J Addict; 2012; 21(3):287-8. PubMed ID: 22494236
    [No Abstract]   [Full Text] [Related]  

  • 16. Psychotic Disorders in Patients Who Use Synthetic Cannabinoids.
    Skryabin VY; Vinnikova MA
    J Psychiatr Pract; 2019 Nov; 25(6):485-490. PubMed ID: 31821228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Spiceophrenia": a systematic overview of "spice"-related psychopathological issues and a case report.
    Papanti D; Schifano F; Botteon G; Bertossi F; Mannix J; Vidoni D; Impagnatiello M; Pascolo-Fabrici E; Bonavigo T
    Hum Psychopharmacol; 2013 Jul; 28(4):379-89. PubMed ID: 23881886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From aberrant salience to jumping to conclusions: dopaminergic pathways to delusions in Parkinson disease.
    Poletti M; Bonuccelli U
    J Clin Psychopharmacol; 2013 Apr; 33(2):149-51. PubMed ID: 23422379
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthetic Cannabinoid Receptor Agonists: a heterogeneous class of novel psychoactive substance with emerging risk of psychosis.
    Whiting D
    Evid Based Ment Health; 2015 Nov; 18(4):110. PubMed ID: 26363038
    [No Abstract]   [Full Text] [Related]  

  • 20. Hallucinations and the spectrum of psychosis in Parkinson's disease.
    Frei K; Truong DD
    J Neurol Sci; 2017 Mar; 374():56-62. PubMed ID: 28108020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.